Henry Schein Acquisitions Expand Its Dental Implant Business

Henry Schein will acquire Intra-Lock as well as majority interests in Medentis Medical and Pro-Cam Implants BV as part of its strategy to advance its dental implant business. Together, these deals represent annual sales of approximately $45 million. They also will be neutral to the company’s 2018 earnings per share and will be accretive thereafter. Financial terms weren’t disclosed.

Targeting the premium implant segment, Intra-Lock provides dental restoration solutions including proprietary surface, connection, and biomaterial and small diameter implant technologies. Focused on the lower-priced segment, Medentis Medical is a dental implant manufacturer based in Germany. Pro-Cam Implants, CAMLOG’s exclusive distributor in the Netherlands, will strengthen Henry Schein’s geographic footprint in Europe.

“The dental implant category has become increasingly important, and we are committed to offering customers a wide array of the products and services associated with implant dentistry, thereby providing a complete solution for the benefit of the dental practice,” said Stanley M. Bergman, chairman of the board and chief executive officer of Henry Schein.

“We believe that with the investments we have made in CAMLOG, BioHorizons, and now Intra-Lock, Medentis Medical, and Pro-Cam Implants, we are well positioned to compete in the high growth global dental implant market. We welcome our new colleagues to Team Schein and look forward to continued success together.”

Intra-Lock International and Intra-Lock Manufacturing are known for their OSSEAN surface structure, which increases host-to-implant biocompatibility and biomechanical response and is characterized by a surface topography that is similar at all levels of magnification. Also, their Intraspin PRF creates platelet-rich fibrin derived from the patient’s blood to enhance wound healing for implant site development.

“As a member of the Henry Schein family, we see tremendous opportunities to continue our legacy of product innovation. We look forward to joining forces with the Henry Schein team to accelerate our growth and to develop and identify technologies that can be leveraged to create next-generation products for BioHorizons and CAMLOG product lines,” said Dr. Thierry Giorno, CEO and director of research and development of Intra-Lock.

Based in Bad Neuenahr-Ahrweiler, Medentis Medical GmbH sells its value-priced dental implants in more than 40 countries and has 75 employees. Founder and CEO Alexander Scholz will continue to lead the business as managing director. Completion of the transaction is subject to regulatory approval and is expected to close in the fourth quarter of 2018.

“With this new ownership position by Henry Schein, Medentis will accelerate several important, ongoing strategic initiatives including expanding our position in the fast-growing emerging markets,” said Scholz. “I am delighted to be aligning Medentis with the global dental leader Henry Schein and look forward to the many opportunities to advance the practice of dentistry.”

Pro-Cam Implants is owned by Mike van Rooijen, who will continue to manage the business and will retain the remaining ownership in the company. The company also will represent the BioHorizons implant lines and biomaterial portfolio.

“By joining forces with CAMLOG and BioHorizons, Pro-Cam Implants will have access to the resources and capital necessary to accelerate our growth in the highly competitive dental implant market,” said van Rooijen. “Working with Henry Schein’s platform in the Netherlands, we see enhanced business prospects and an opportunity to solidify market share gains in the future.”